Effect of capecitabine on breast cancer patients with different estrogen receptor status

Authors

  • Gang Xu Department of General Surgery, Zhejiang Hospital, City of Hangzhou, Zhejiang Province 310013, China.
  • Xin Lv Fourth Wards of General Surgery, Shengzhou People’s Hospital (The First Affiliated Hospital of Zhejiang University Shengzhou Branch), City of Shengzhou, Zhejiang Province 312400, China.
  • Ke Lu The First Surgical Department, The Affiliated Hangzhou Xixi Hospital of Zhejiang Chinese Medical University, City of Hangzhou, Zhejiang Province, 310023, China.
  • Ming Hai Shen The First Surgical Department, The Affiliated Hangzhou Xixi Hospital of Zhejiang Chinese Medical University, City of Hangzhou, Zhejiang Province, 310023, China.
  • Qing Hua Zhang The First Surgical Department, The Affiliated Hangzhou Xixi Hospital of Zhejiang Chinese Medical University, City of Hangzhou, Zhejiang Province, 310023, China.
  • Wan Neng Pan The First Surgical Department, The Affiliated Hangzhou Xixi Hospital of Zhejiang Chinese Medical University, City of Hangzhou, Zhejiang Province, 310023, China.

DOI:

https://doi.org/10.3329/bjp.v15i2.43522

Keywords:

Breast cancer, Capecitabine, Chemotherapy, Estrogen receptor

Abstract

This meta-analysis is to compare the efficacy of capecitabine versus non-capecitabine chemotherapy on breast cancer patients with different estrogen receptor (ER) status. We searched relevant literatures from EMBASE, PubMed and OVID library to analyze pathologic complete response rate (PCR), overall survival (OS), disease-free survival (DFS), progression-free survival (PFS), and time to disease progression (TTP). Eleven different studies were enrolled, which revealed that ER positive breast cancer patients who received treatment regimen containing capecitabine can effectively improve PFS, PCR, TTP. However, the difference between capecitabine-containing and non-capecitabine group has no significant for DFS, OS. ER negative breast cancer patients who received treatment regimen containing capecitabine can obviously improve DFS and TTP. However, there was no significant effect for PFS, PCR and OS. The results indicated that capecitabine in combination with other chemotherapy drugs for breast cancer is effective, which can delay the progression time in patients to some extent.

Downloads

Download data is not yet available.
Abstract
30
Download
18

Downloads

Published

2020-07-04

How to Cite

Xu, G., X. Lv, K. Lu, M. H. Shen, Q. H. Zhang, and W. N. Pan. “Effect of Capecitabine on Breast Cancer Patients With Different Estrogen Receptor Status”. Bangladesh Journal of Pharmacology, vol. 15, no. 2, July 2020, pp. 47-57, doi:10.3329/bjp.v15i2.43522.

Issue

Vol. 15 No. 2 (2020)

Section

Meta-Analysis

License

Authors who publish with this journal agree to the following terms:

  1. Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
  2. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
  3. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).